Introduction
Pancreatic enzyme insufficiency is common in cystic fibrosis and is predominantly responsible for the maldigestion of fat and protein. Preparations of animal pancreas given by mouth reduce stool fat and nitrogen losses but normal faecal levels are rarely achieved (Harris et al., 1955; Ross, 1955; Matthews and Spector, 1961; Lapey et al., 1974) .
Consequently we were interested to examine the effects in children of a different preparation, Nutrizym, which in comparison with Pancrex V forte was reported by Knill-Jones et al. (1970) , in a study on 12 young adults, 11 of whom had cystic fibrosis, to be significantly more effective in improving fat absorption. Some reduction of faecal weight and improvement in protein digestion with Nutrizym were also recorded by these authors.
Composition and Action of Tablets Nutrizym tablets are of composite structure with an external sugar coating which dissolves in gastric contents at a pH of between 3 and 8 to uncover a shell of bromelain, a proteolytic enzyme derived from pineapple. Unlike trypsin this enzyme is said to be active both in the stomach and in the small gut. The next layer, an enteric coat, disintegrates at a pH of 6-0 to 8-5 to release a central core of pancreatin powder and 30 mg of an ox bile preparation, of which 45% is cholic acid.
Pancrex V forte tablets are enteric coated, the coating being designed to disintegrate at a pH of 6 or over to release Pancrex V powder.
In Fat intake was that provided by the usual home diet and parents recorded the type and quantity of all food taken during each week of the four-week period. Medicines were also recorded. In addition parents and children kept an account of the daily number of bowel actions, describing stool odour and consistency; abdominal pain, "wind," and incidental illnesses were also noted. An assessment of product palatability was made at the completion of the trial, and participants were asked if they had a preference for either product and if so to give reasons for this preference.
Three-day stool collections and 24-hour urine collections (containing 1 ml of sodium azide 20 g/100 ml) were made at the end of each week of the four-week trial. An assessment of the effectiveness of the tablets was made by comparison of stool volume, number of bowel actions, faecal fat excretion, and urine urea excretion during the two-week periods on each preparation. The choice of urine urea was based on the report of Coltini et al. (1973) , who, in a study of nitrogen balance in adults without known malabsorption problems, described a positive correlation between urine urea and nitrogen absorption which was independent of the state of nitrogen balance. Thus an improvement of nitrogen absorption with the use of either of the preparations should have been reflected in an increase in the excretion of urea.
LABORATORY MEASUREMENTS
Faecal fat analysis was performed by the method of Van de Kamer et al. (1949) as modified by Anderson et al. (1952) . Urine urea was estimated by the method of Fawcett and Scott (1960) and urine creatinine by the method of Bonsnes and Taussky (1945) . Urea excretion was expressed in g/24 hours, and because of the problems inherent in the collection of accurately timed urine specimens from children it was also expressed as g of urea/mg of creatinine/24 hours. The results for the 12 subjects are combined in table II. About half the number of Nutrizym tablets were taken compared with Pancrex V forte, to conform to the different enzyme contents of the tablets, and the mean figures for stool volume, number of bowel actions, and faecal fat excretion were similar with the two preparations.
PARENT'S RECORDS Information on the fat intake recorded each day by the parents and discussions between the parents and the dietician (H.R.J.) allowed calculation of the children's fat intake while they were on Pancrex V forte and Nutrizym. Mean values over 24 hours were calculated on a two-day and a three-day basis for each child for each week and the close similarity between the figures suggested that the two-day mean value was adequate to compare the fat intake on each enzyme preparation (for the group as a whole two-and three-day mean fat intakes on Pancrex V forte were 65-5 and 65-2 g/24 hours respectively and two-and threeday mean fat intakes on Nutrizym were 64-7 and 64-9 g/24 hours respectively). Figures for fat intake, faecal fat, and coefficients of fat absorption are shown in table III. In two children (cases 2 and 5) the coefficient of fat absorption was nil, and in the others the figures ranged from 52-4% (case 3) to 90 3% (case 9). With the exclusion of cases 2 and 5 the mean coefficients of absorption on Pancrex V forte and Nutrizym were 701% and 69 2% respectively.
The record sheets also showed that medicines were not altered during the trial. The change from Nutrizym to Pancrex V forte resulted in no striking differences in stool character or in the occurrence of abdominal pain or "wind." Incidental illnesses were few and were judged to have played little part in the food intake and bowel pattern.
FINAL QUESTIONNAIRE
This questionnaire was completed by the parents at the end of the trial. Of the 12 patients nine preferred Nutrizym, one preferred Pancrex V forte, and two thought that the products were of equal effect.
Of the nine patients who preferred Nutrizym three did so solely because they considered that the product was easier and more pleasant to take (a reflection in part of the reduced number of tablets); three others agreed with this and thought in addition that stools were less frequent and more formed and that abdominal pain and "wind" were decreased; two commented on an improved stool character and less abdominal pain, and one gave more formed stools as the reason for his choice. The patient who preferred Pancrex V forte did so on account of more formed and less frequent stools.
Discussion
We have been unable to confirm the results of Knill-Jones et al. (1970) , who reported a decrease in faecal fat excretion of 14-8 g/day when their patients were on Nutrizym (mean fat excretion 42-5 g) compared with when they were on Pancrex V forte (mean fat excretion 57-3 g). Our patients' fat excretion was closely similar with both products (25 3 g on Nutrizym and 24-3 g on Pancrex V forte). Before the start of our trial patients had been taking Pancrex V forte in a dosage which had been established by the parents as being the most effective one for reducing stool frequency and improving stool character. All patients continued with this regimen for the first two weeks of the trial so that dosage and relevant details could be recorded, and the number of tablets was halved (though the enzyme dose for trypsin and lipase remained the same) during the two weeks when Nutrizym was given. Knill-Jones et al. (1970) chose to use suboptimal doses of pancreatic replacement therapy to facilitate the detection of improved digestion with either of the two preparations. Our doses resulted in smaller faecal fat excretions, but these were still sufficiently abnormal, we believe, for any differences in the effectiveness of the tablets to be apparent. In addition we did not find a significant difference in stool volume (mean volume 294 ml/day on Nutrizym and 259 ml/day on Pancrex V forte). Knill-Jones et al. (1970) Though the laboratory investigations did not provide any evidence in favour of either product the final questionnaire completed by the parents showed some patient preference for Nutrizym. There was some discrepancy (unexplained) between the information on stool frequency and character and the occurrence of abdominal pain obtained during the course of the trial, when there was no patient preference, and the information obtained at the end, when some of the parents modified their views in favour of Nutrizym. Clearly it is more convenient, especially for those patients who take a high dose of pancreatic preparation, to be able to reduce the number of tablets.
With the exception of the two children whose coefficients of fat absorption were nil (table III) values obtained for the children while on pancreatic replacement therapy were comparable with those in previous reports (Harris et al., 1955; Ross, 1955; Matthew and Spector, 1961) , and the mean value (70%) was some 28% less than normal (96% i 40) (Matthews and Spector, 1961) .
The apparent absence of fat absorption in cases 2 and 5 is difficult to explain. Both children were taking high doses of pancreatic therapy (mean numbers of Pancrex V forte and Nutrizym tablets per week were 133 and 63 respectively for case 2, and 378 and 214 respectively for case 5). One patient (case 2), aged 6-6 years, was on the 75th centile for weight, and the other (case 5), aged 8-7 years, was on the 10th centile.
Pancreatic enzyme preparations, even in high dosage, do not eliminate the steatorrhoea of cystic fibrosis and it seems expedient to investigate other mechanisms which may influence fat absorption in this disease.
